Among patients with breast cancer aged up to 31 y.o., the proportion of carriers of pathogenic TP53 variants was 3.0% (3/100), aligning with previously reported rates of 3.8%-6.0% for patients ≤ 31 y.o. [19, 20]. This evidence concerns the gene TP53 and breast cancer.